Previously the company announced that data from a study presented at the recently convened Annual Congress of the Swiss Society of Cardiology concluded that MCP (Muscular CounterPulsation) is safe and efficient for improving cardiac function non-surgically in patients with coronary artery disease (CAD). In the study, peripheral resistance of CAD patients was decreased by 22%, end-diastolic pressure was reduced by 18%, and stroke work was reduced by 16%. Additionally, there was a 12% increase in cardiac index. Equally important, all of these hemodynamic effects were less marked in the study’s control patients.

“We are extremely pleased with our headway in penetrating the European market with our m.pulse system, based on Muscular CounterPulsation or MCP, for the non-surgical treatment of coronary artery disease. Certainly, it is well-documented clinically that MCP, the proprietary technology platform of our patented m.pulse device, is a safe and effective therapy designed to improve the hemodynamic function of a failing heart,” said Christof Lenz, Cardiola’s chief executive officer and former Global Innovation Manager at Siemens Medical. “Ten hospitals in Germany and Switzerland are now using the m.pulse system on a regular basis, thus giving their patients a well-validated, affordable and non-surgical treatment option that patients themselves can perform in their own home. We expect to report considerably more progress in our goal to ensconce m.pulse across Europe as standard adjuvant care for treating CAD at home.”

Cardiola’s m.pulse device, based on Muscular CounterPulsation (MCP) technology, is approved in Europe for treating CHF as a non-surgical, at-home therapy. Battery-powered m.pulse, the size of a cell phone that the patient attaches to his belt for about 45 minutes per treatment, is synchronized to his cardiac cycle to stimulate the muscles of the calves and thighs to make them contract in the resting phase of the heart. This well-established Muscular CounterPulsation action results in increased blood flow to the heart muscle while decreasing the heart’s workload. MCP was previously only available in a clinical setting.